RELATED CONTENT
News | Prostate Cancer
April 19, 2022 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...
April 19, 2022 
September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...
September 17, 2021 
News | Radiation Therapy
May 25, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...
May 25, 2021 
News | PET Imaging
January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...
January 18, 2021 
News | Contrast Media Injectors
November 17, 2020 — Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging ...
November 17, 2020 
News | Radiology Business
November 3, 2020 — The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded the 20 ...
November 03, 2020 
News | Contrast Media
January 17, 2020 — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading ...
January 17, 2020 
News | Contrast Media
December 10, 2019 — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in ...
December 10, 2019 
Technology | Contrast Media
Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium sulfate) for oral suspension, which is indicated for modified barium swallow (MBS) studies. The contrast agent is used to detect and assess the type and severity of swallowing disorders also known as dysphagia.
August 05, 2019 
Feature | Contrast Media | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are now ...
July 18, 2019